chloroquine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
quinoline derivatives 607 54-05-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chloroquine sulfate
  • chloroquine
  • chloroquine phosphate
  • chloraquine
  • chlorochin
  • chloroquine hydrochloride
  • chloroquine diphosphate
  • chloroquine HCl
  • chloroquine sulphate
The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. In March 2020, FDA issued an emergency use authorization (EUA) for hydroxychloroquine and chloroquine in the treatment of COVID-10. EUA was revoked in June 2020. Data from various published randomized, controlled clinical trials and retrospective, cohort studies have not substantiated initial reports of efficacy of 4-aminoquinoline antimalarials for treatment of COVID-19.
  • Molecular weight: 319.88
  • Formula: C18H26ClN3
  • CLOGP: 5.06
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 1
  • TPSA: 28.16
  • ALOGS: -4.26
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g O
0.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 61 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 46.89 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 140 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.43 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 570 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MET,NTRK2,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1 35
kinase-selectivity-class AXL,EIF2AK3,PDK4 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.472 High 0.87
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
rat-kpuu-brain Rat brain Kpuu 0.180 % High 0.87

Approvals:

DateAgencyCompanyOrphan
Oct. 31, 1949 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood parathyroid hormone decreased 135.00 17.90 51 10105 12165 90606126
Panniculitis 133.60 17.90 53 10103 14405 90603886
Granuloma skin 130.50 17.90 48 10108 10632 90607659
Treatment failure 125.51 17.90 162 9994 303766 90314525
Hepatitis 124.87 17.90 85 10071 70654 90547637
Rheumatoid nodule 116.60 17.90 53 10103 20113 90598178
Skin necrosis 115.56 17.90 50 10106 16891 90601400
Breath sounds abnormal 113.50 17.90 48 10108 15338 90602953
Necrotising herpetic retinopathy 108.97 17.90 18 10138 121 90618170
Basal cell carcinoma 102.12 17.90 57 10099 33332 90584959
C-reactive protein increased 91.41 17.90 107 10049 181282 90437009
Hypercalcaemia 84.89 17.90 51 10105 34189 90584102
Ulcer 84.18 17.90 50 10106 32832 90585459
Red blood cell sedimentation rate increased 81.07 17.90 70 10086 82525 90535766
Skin ulcer 80.88 17.90 57 10099 50018 90568273
Aspartate aminotransferase increased 79.03 17.90 76 10080 102861 90515430
Drug eruption 78.24 17.90 49 10107 35358 90582933
Arthritis 74.96 17.90 93 10063 167222 90451069
Skin neoplasm excision 72.76 17.90 20 10136 1726 90616565
Pulmonary fibrosis 72.57 17.90 74 10082 107429 90510862
Condition aggravated 71.06 17.90 185 9971 595360 90022931
Prescribed underdose 62.55 17.90 58 10098 74961 90543330
Rheumatoid factor positive 57.79 17.90 83 10073 171567 90446724
Central nervous system lymphoma 56.29 17.90 17 10139 2048 90616243
Off label use 54.22 17.90 255 9901 1101997 89516294
Alanine aminotransferase increased 53.32 17.90 66 10090 118272 90500019
Drug tolerance decreased 52.86 17.90 37 10119 32093 90586198
Jaw clicking 50.36 17.90 9 10147 101 90618190
Dermatitis 49.70 17.90 31 10125 22189 90596102
Weber tuning fork test abnormal 49.65 17.90 9 10147 110 90618181
Deafness 49.33 17.90 31 10125 22483 90595808
Atrioventricular block complete 48.06 17.90 23 10133 9788 90608503
Inflammation 46.92 17.90 77 10079 178515 90439776
Neoplasm skin 45.43 17.90 16 10140 3126 90615165
Retinal toxicity 44.39 17.90 13 10143 1409 90616882
Synovitis 43.96 17.90 107 10049 329645 90288646
Rash pruritic 42.18 17.90 49 10107 82165 90536126
Musculoskeletal stiffness 41.43 17.90 98 10058 296434 90321857
Therapeutic product effect incomplete 41.04 17.90 76 10080 193820 90424471
Drug ineffective 38.88 17.90 276 9880 1384022 89234269
Drug intolerance 37.75 17.90 123 10033 447468 90170823
Loss of personal independence in daily activities 37.53 17.90 60 10096 136045 90482246
Hepatitis viral 34.43 17.90 9 10147 641 90617650
Hepatic enzyme increased 33.95 17.90 103 10053 360633 90257658
Amaurosis 32.25 17.90 9 10147 821 90617470
Varicella zoster virus infection 31.62 17.90 13 10143 3864 90614427
Cutaneous leishmaniasis 30.67 17.90 6 10150 113 90618178
Secondary adrenocortical insufficiency 30.47 17.90 11 10145 2307 90615984
Hypersensitivity 29.77 17.90 115 10041 454562 90163729
Maculopathy 29.63 17.90 11 10145 2495 90615796
Therapeutic response decreased 28.15 17.90 42 10114 89687 90528604
Drug tolerance 28.00 17.90 20 10136 17896 90600395
Petechiae 27.94 17.90 19 10137 15722 90602569
Attention deficit hyperactivity disorder 27.38 17.90 12 10144 4172 90614119
Disseminated tuberculosis 26.70 17.90 11 10145 3288 90615003
Acquired pigmented retinopathy 26.60 17.90 4 10152 13 90618278
Ventricular hypertrophy 26.41 17.90 11 10145 3380 90614911
Erythema 25.96 17.90 70 10086 229176 90389115
Ocular toxicity 25.68 17.90 8 10148 1069 90617222
Muscle contracture 25.29 17.90 9 10147 1812 90616479
Interferon gamma release assay positive 25.04 17.90 5 10151 105 90618186
Contraindicated product administered 24.32 17.90 85 10071 320054 90298237
Insomnia 24.01 17.90 87 10069 333387 90284904
Diarrhoea 23.95 17.90 43 10113 939147 89679144
Rheumatoid arthritis 23.94 17.90 92 10064 362522 90255769
Mucocutaneous leishmaniasis 23.41 17.90 6 10150 395 90617896
Oral mucosa erosion 23.13 17.90 8 10148 1481 90616810
Carcinoembryonic antigen increased 23.05 17.90 9 10147 2341 90615950
Type V hyperlipidaemia 22.88 17.90 7 10149 881 90617410
Pneumonia 22.50 17.90 135 10021 637924 89980367
Areflexia 22.37 17.90 10 10146 3643 90614648
Drug ineffective for unapproved indication 22.06 17.90 32 10124 66612 90551679
Gastrointestinal disorder 22.00 17.90 71 10085 256616 90361675
Toxic encephalopathy 21.66 17.90 13 10143 8686 90609605
Cinchonism 21.00 17.90 3 10153 6 90618285
Cardiotoxicity 20.82 17.90 14 10142 11375 90606916
Nerve degeneration 20.78 17.90 4 10152 69 90618222
Hypertension 20.26 17.90 103 10053 457429 90160862
Dyslipidaemia 19.87 17.90 13 10143 10094 90608197
Restrictive cardiomyopathy 19.50 17.90 5 10151 330 90617961
Hepatic pain 19.36 17.90 9 10147 3586 90614705
Constipation 19.21 17.90 4 10152 280391 90337900
Product use issue 18.81 17.90 80 10076 329839 90288452
Therapeutic product effect decreased 17.96 17.90 70 10086 277501 90340790
Glomerulonephritis chronic 17.93 17.90 4 10152 145 90618146

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 210.98 28.35 198 1828 638137 41981172
Maculopathy 42.84 28.35 10 2016 1065 42618244
Pneumococcal infection 37.77 28.35 8 2018 546 42618763
Dry gangrene 32.74 28.35 7 2019 500 42618809
Malaria 32.19 28.35 6 2020 212 42619097
Rales 28.89 28.35 13 2013 11387 42607922

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 171.65 17.93 436 11062 1499749 109078052
Blood parathyroid hormone decreased 135.28 17.93 51 11447 13038 110564763
Granuloma skin 131.42 17.93 48 11450 11235 110566566
Panniculitis 130.11 17.93 52 11446 15530 110562271
Rheumatoid nodule 120.07 17.93 53 11445 20243 110557558
Treatment failure 118.67 17.93 145 11353 277089 110300712
Hepatitis 107.71 17.93 83 11415 89971 110487830
Skin necrosis 107.69 17.93 50 11448 21462 110556339
Necrotising herpetic retinopathy 104.23 17.93 18 11480 177 110577624
Breath sounds abnormal 93.93 17.93 48 11450 25356 110552445
Basal cell carcinoma 85.03 17.93 55 11443 45215 110532586
C-reactive protein increased 83.63 17.93 108 11390 217811 110359990
Pulmonary fibrosis 76.65 17.93 72 11426 101970 110475831
Red blood cell sedimentation rate increased 76.24 17.93 64 11434 78238 110499563
Ulcer 75.16 17.93 50 11448 43066 110534735
Hypercalcaemia 73.93 17.93 51 11447 46606 110531195
Prescribed underdose 73.42 17.93 58 11440 65116 110512685
Skin ulcer 72.47 17.93 57 11441 63588 110514213
Arthritis 72.16 17.93 88 11410 167498 110410303
Rheumatoid factor positive 71.61 17.93 78 11420 131562 110446239
Skin neoplasm excision 70.98 17.93 20 11478 2038 110575763
Drug eruption 65.32 17.93 50 11448 53609 110524192
Maculopathy 63.37 17.93 20 11478 3007 110574794
Drug tolerance decreased 60.59 17.93 37 11461 27503 110550298
Aspartate aminotransferase increased 59.35 17.93 78 11420 159858 110417943
Condition aggravated 59.15 17.93 189 11309 734647 109843154
Atrioventricular block complete 57.47 17.93 32 11466 20050 110557751
Jaw clicking 51.53 17.93 9 11489 95 110577706
Central nervous system lymphoma 51.05 17.93 17 11481 3027 110574774
Weber tuning fork test abnormal 50.32 17.93 9 11489 110 110577691
Inflammation 48.04 17.93 78 11420 193160 110384641
Deafness 46.60 17.93 31 11467 26678 110551123
Neoplasm skin 46.29 17.93 16 11482 3188 110574613
Dermatitis 45.44 17.93 31 11467 27806 110549995
Synovitis 43.32 17.93 91 11407 274001 110303800
Acquired pigmented retinopathy 41.81 17.93 6 11492 14 110577787
Drug ineffective 41.16 17.93 284 11214 1520256 109057545
Alanine aminotransferase increased 40.11 17.93 70 11428 183703 110394098
Therapeutic product effect incomplete 38.54 17.93 77 11421 223728 110354073
Rash pruritic 38.18 17.93 49 11449 98020 110479781
Loss of personal independence in daily activities 37.88 17.93 61 11437 149959 110427842
Musculoskeletal stiffness 34.29 17.93 84 11414 279738 110298063
Hypersensitivity 33.38 17.93 105 11393 403893 110173908
Drug intolerance 32.99 17.93 105 11393 406407 110171394
Hepatic enzyme increased 32.82 17.93 90 11408 320802 110256999
Contraindicated product administered 31.99 17.93 76 11422 248191 110329610
Restrictive cardiomyopathy 30.73 17.93 9 11489 1052 110576749
Cardiotoxicity 30.43 17.93 20 11478 16861 110560940
Insomnia 29.12 17.93 93 11405 360497 110217304
Drug tolerance 28.33 17.93 19 11479 16566 110561235
Hepatitis viral 27.81 17.93 9 11489 1466 110576335
Arthropathy 27.77 17.93 79 11419 287443 110290358
Joint swelling 27.76 17.93 105 11393 442740 110135061
Plasmodium vivax infection 27.68 17.93 4 11494 10 110577791
Attention deficit hyperactivity disorder 27.43 17.93 12 11486 4479 110573322
Amaurosis 27.15 17.93 9 11489 1580 110576221
Therapeutic product effect decreased 26.45 17.93 70 11428 244246 110333555
Varicella zoster virus infection 26.37 17.93 13 11485 6355 110571446
Therapeutic response decreased 25.39 17.93 40 11458 96459 110481342
Cinchonism 25.05 17.93 4 11494 23 110577778
Electrocardiogram QT prolonged 24.40 17.93 42 11456 108918 110468883
Secondary adrenocortical insufficiency 24.36 17.93 11 11487 4423 110573378
Cutaneous leishmaniasis 23.95 17.93 6 11492 389 110577412
Diarrhoea 23.85 17.93 52 11446 1139453 109438348
Drug ineffective for unapproved indication 23.51 17.93 40 11458 102798 110475003
Malaria 23.48 17.93 6 11492 421 110577380
Hypertension 23.43 17.93 110 11388 509974 110067827
Oral mucosa erosion 23.35 17.93 9 11489 2439 110575362
Disseminated tuberculosis 22.80 17.93 11 11487 5135 110572666
Petechiae 22.56 17.93 19 11479 23298 110554503
Constipation 22.21 17.93 5 11493 357781 110220020
Mucocutaneous leishmaniasis 22.19 17.93 6 11492 525 110577276
Muscle contracture 22.15 17.93 9 11489 2799 110575002
Pneumococcal infection 22.15 17.93 8 11490 1811 110575990
Dry gangrene 22.15 17.93 7 11491 1057 110576744
Carcinoembryonic antigen increased 22.10 17.93 9 11489 2815 110574986
Product use issue 21.27 17.93 76 11422 311619 110266182
Product use in unapproved indication 20.92 17.93 97 11401 447280 110130521
Anaemia 20.66 17.93 16 11482 547070 110030731
Death 20.04 17.93 26 11472 698843 109878958
Areflexia 19.95 17.93 11 11487 6758 110571043
Type V hyperlipidaemia 19.87 17.93 7 11491 1475 110576326
Ventricular hypertrophy 19.54 17.93 11 11487 7034 110570767
Gastrointestinal disorder 19.14 17.93 62 11436 241890 110335911
Retinal toxicity 19.10 17.93 7 11491 1652 110576149
Erythema 18.98 17.93 70 11428 291377 110286424
Hypotension 18.93 17.93 16 11482 523833 110053968

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC P01BA01 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
ANTIMALARIALS
Aminoquinolines
ATC P01BB52 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
ANTIMALARIALS
Biguanides
FDA EPC N0000175482 Antimalarial
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:38068 antimalarial
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:75835 anti-anaemic agent
CHEBI has role CHEBI:88230 autophagy inhibitor
CHEBI has role CHEBI:149553 anticoronaviral agent
MeSH PA D000700 Analgesics
MeSH PA D000871 Anthelmintics
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D000962 Antimalarials
MeSH PA D000969 Antinematodal Agents
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
MeSH PA D005369 Filaricides
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018501 Antirheumatic Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000563 Amebicides
CHEBI has role CHEBI:38070 anti-arrhythmia drug

Related Drugs by ATC class:

P01BA Aminoquinolines 4 drugs
amodiaquinehydroxychloroquineprimaquinetafenoquine
P01BB Biguanides 3 drugs
atovaquonecycloguanilproguanil

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ovale malaria indication 19341001 DOID:12919
Vivax malaria indication 27052006 DOID:12978
Quartan malaria indication 27618009 DOID:14324
Systemic lupus erythematosus indication 55464009 DOID:9074
Falciparum malaria indication 62676009 DOID:14067
Rheumatoid arthritis indication 69896004 DOID:7148
Discoid lupus erythematosus indication 200938002
Plasmodium Malariae Malaria Prevention indication
Plasmodium Ovale Malaria Prevention indication
Malaria Prevention indication
Plasmodium Falciparum Malaria Prevention indication
Vasculitis of the skin off-label use 53312001
Porphyria cutanea tarda off-label use 61860000 DOID:3132
Q fever endocarditis off-label use 95890006
Coronavirus infection off-label use 186747009
Polymorphic light eruption off-label use 238525001
Juvenile rheumatoid arthritis off-label use 410795001
Hypercalcemia associated with Sarcoidosis off-label use
Alcoholism contraindication 7200002
Psoriasis contraindication 9014002 DOID:8893
Visual field defect contraindication 12184005
Retinal disorder contraindication 29555009 DOID:5679
Leukopenia contraindication 84828003 DOID:615
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Hearing disorder contraindication 128540005
Seizure disorder contraindication 128613002
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Neutropenic disorder contraindication 303011007 DOID:1227
Disorder of macula of retina contraindication 312999006
Disorder of eye contraindication 371405004 DOID:5614
Visual impairment contraindication 397540003
Porphyria contraindication 418470004




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Euthanasia Indication

🐶 Veterinary products

ProductApplicantIngredients
Tributame Euthanasia Solution Cronus Pharma Specialities India Private Limited 3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.19 Basic
pKa2 7.83 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-2A adrenergic receptor GPCR Ki 5.36 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.10 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.60 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 4.50 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 5.04 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 5.33 CHEMBL
Muscarinic acetylcholine receptor M3 GPCR Ki 5.48 CHEMBL
Muscarinic acetylcholine receptor M4 GPCR Ki 5.24 CHEMBL
Muscarinic acetylcholine receptor M5 GPCR Ki 4.66 CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 5 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme IC50 5.82 CHEMBL
Serine/threonine-protein kinase mTOR Kinase IC50 6.57 CHEMBL
C-X-C chemokine receptor type 4 GPCR EC50 5.19 CHEMBL
Beta-secretase 1 Enzyme IC50 5.16 CHEMBL
Major prion protein Surface antigen EC50 5.40 CHEMBL
Amyloid beta A4 protein Membrane other IC50 5.16 CHEMBL
Transmembrane protein 97 Enzyme Ki 6.30 CHEMBL
Nuclear receptor subfamily 4 group A member 2 Nuclear other EC50 4.33 CHEMBL
Histidine-rich protein PFHRP-II Cytosolic other IC50 6.40 CHEMBL
Riboflavin-binding protein Secreted Kd 5.68 CHEMBL
Dihydrofolate reductase Enzyme IC50 7.52 CHEMBL
Replicase polyprotein 1ab Enzyme IC50 5.14 CHEMBL
Spike glycoprotein Glycoprotein IC50 6.80 CHEMBL
Cysteine proteinase falcipain 2a Enzyme IC50 7.70 CHEMBL
NACHT, LRR and PYD domains-containing protein 3 Cytosolic other IC50 4.06 CHEMBL
Cysteine proteinase falcipain 2a Enzyme IC50 6.70 CHEMBL

External reference:

IDSource
D02125 KEGG_DRUG
132-73-0 SECONDARY_CAS_RN
50-63-5 SECONDARY_CAS_RN
203119 RXNORM
C0008269 UMLSCUI
CHEBI:3638 CHEBI
CLQ PDB_CHEM_ID
CHEMBL76 ChEMBL_ID
CHEMBL2095223 ChEMBL_ID
CHEMBL58510 ChEMBL_ID
DB00608 DRUGBANK_ID
CHEMBL4297165 ChEMBL_ID
D002738 MESH_DESCRIPTOR_UI
2719 PUBCHEM_CID
5535 IUPHAR_LIGAND_ID
386 INN_ID
3545-67-3 SECONDARY_CAS_RN
886U3H6UFF UNII
3949 MMSL
4417 MMSL
4418 MMSL
d00035 MMSL
002938 NDDF
002939 NDDF
002940 NDDF
004124 NDDF
14728000 SNOMEDCT_US
373468005 SNOMEDCT_US
395937005 SNOMEDCT_US
53136009 SNOMEDCT_US
60266005 SNOMEDCT_US
4018227 VANDF
4018228 VANDF
4019675 VANDF
C023676 MESH_SUPPLEMENTAL_RECORD_UI
886U3H6UFF INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Chloroquine Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0115-2790 TABLET 250 mg ORAL ANDA 20 sections
Chloroquine Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0115-7010 TABLET 500 mg ORAL ANDA 20 sections
Chloroquine Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 23155-850 TABLET, COATED 500 mg ORAL ANDA 22 sections
Chloroquine Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42291-047 TABLET 500 mg ORAL ANDA 20 sections
CHLOROQUINE PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 62135-717 TABLET, COATED 500 mg ORAL ANDA 12 sections
Chloroquine Phosphate Human Prescription Drug Label 1 64980-177 TABLET 250 mg ORAL ANDA 14 sections
Chloroquine Phosphate Human Prescription Drug Label 1 64980-178 TABLET 500 mg ORAL ANDA 15 sections